Watch More Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses key information for advanced practitioners on the B-cell maturation antigen, a target for multiple myeloma, and CAR T-cell therapy, now approved for relapsed or refractory disease. Although the results have been encouraging, relapses still occur, highlighting the need to understand how best to sequence the regimen and the role of antibody-drug conjugates, bispecific antibodies, and CAR-T cells.

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.